Skip to main content
PGNYNasdaqinactive

Progyny Inc.

·New York, NY, United States·CEO: Mr. Peter Anevski CPA

PGNY evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for PGNY—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

6.1/10

BioSniper Score

Based on 3 of 6 signals

Limited data coverage

Market Cap

$2.04B

Cash Runway

Lead Asset

Next Catalyst

Financial data as of Mar 31, 2026.

Run Progyny Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Progyny Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 3 of 6 signals · derived from public data

No clinical pipeline tracked — this score reflects financial & catalyst signals only.

Cash Runway10.0

Profitable (positive operating cash flow)

Financial Health8.3

D/E 0.59 · 8% dilution

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline BreadthN/A

No tracked pipeline candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider Signal0.0

0 buys · 14 sells (180d)

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

290

Total value held

$1.31B

HolderSharesValue
blackrock, inc.11,998,467$203.7M
fmr llc6,500,819$110.4M
vanguard portfolio management llc5,292,028$89.9M
vanguard capital management llc3,481,339$59.1M
state street corp3,080,293$52.3M
ameriprise financial inc2,825,331$48.0M
fort washington investment advisors inc /oh/2,693,393$45.7M
morgan stanley2,287,617$38.8M
wellington management group llp2,287,381$38.8M
geode capital management, llc2,042,965$34.7M

Showing top 10 of 290 institutional holders of Progyny Inc.. Open the full 13F history after sign-in.

Short Interest

as of Apr 30, 2026
% of float
9.9%
Days to cover
4.2
Shares short
5,531,407
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

PGNY short interest

Governance

Frequently asked questions

Who is the CEO of Progyny Inc.?

Mr. Peter Anevski CPA is the chief executive officer of Progyny Inc. (PGNY).

Where is Progyny Inc. headquartered?

Progyny Inc. (PGNY) is headquartered in New York, NY, United States.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.